Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 5/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.40 |
| ▸ | EDNRB | P24530 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | KDM6B | O15054 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.36 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317664 | 0.93 | EDNRA (0.40) | EDNRAGABRA5EDNRBKDM4EKDM6B | |
| SCHEMBL6318219 | 0.89 | EDNRA (0.42) | EDNRAGABRA5EDNRBKDM4EKMT2A | |
| SCHEMBL6324589 | 0.88 | EDNRA (0.48) | EDNRAEDNRBMETAP2P4HTM | |
| SCHEMBL6317657 | 0.83 | GLO1 (0.41) | EDNRAGABRA5KDM4EKMT2AMEN1 | |
| SCHEMBL6315510 | 0.83 | MEN1 (0.40) | EDNRAEDNRBKMT2AMEN1 | |
| SCHEMBL6315797 | 0.82 | KDM4E (0.51) | EDNRAKDM4EKMT2AMEN1PFKFB3 | |
| SCHEMBL6318435 | 0.81 | KDM4E (0.57) | KDM4EKMT2AMEN1 | |
| SCHEMBL6324666 | 0.81 | GAA (0.42) | EDNRAKDM4EKMT2AMEN1 | |
| SCHEMBL6324765 | 0.81 | TP53 (0.50) | KDM4EKDM4AKMT2AMEN1 | |
| SCHEMBL6318656 | 0.79 | NPC1 (0.50) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | claimed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | EDNRA 4545/4885GABRA5 742/4885EDNRB 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.